Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
J Pharmacol Exp Ther ; 384(3): 382-392, 2023 03.
Article in English | MEDLINE | ID: mdl-36507845

ABSTRACT

Activation of soluble guanylate cyclase (sGC) to restore cyclic guanosine monophosphate (cGMP) and improve functionality of nitric oxide (NO) pathways impaired by oxidative stress is a potential treatment of diabetic and chronic kidney disease. We report the pharmacology of BI 685509, a novel, orally active small molecule sGC activator with disease-modifying potential. BI 685509 and human sGC α1/ß1 heterodimer containing a reduced heme group produced concentration-dependent increases in cGMP that were elevated modestly by NO, whereas heme-free sGC and BI 685509 greatly enhanced cGMP with no effect of NO. BI 685509 increased cGMP in human and rat platelet-rich plasma treated with the heme-oxidant ODQ; respective EC50 values were 467 nM and 304 nM. In conscious telemetry-instrumented rats, BI 685509 did not affect mean arterial pressure (MAP) or heart rate (HR) at 3 and 10 mg/kg (p.o.), whereas 30 mg/kg decreased MAP and increased HR. Ten days of BI 685509 at supratherapeutic doses (60 or 100 mg/kg p.o., daily) attenuated MAP and HR responses to a single 100 mg/kg challenge. In the ZSF1 rat model, BI 685509 (1, 3, 10, and 30 mg/kg per day, daily) coadministered with enalapril (3 mg/kg per day) dose-dependently reduced proteinuria and incidence of glomerular sclerosis; MAP was modestly reduced at the higher doses versus enalapril. In the 7-day rat unilateral ureteral obstruction model, BI 685509 dose-dependently reduced tubulointerstitial fibrosis (P < 0.05 at 30 mg/kg). In conclusion, BI 685509 is a potent, orally bioavailable sGC activator with clear renal protection and antifibrotic activity in preclinical models of kidney injury and disease. SIGNIFICANCE STATEMENT: BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a rat 7-day unilateral ureteral obstruction model. Thus, BI 685509 is a promising new therapeutic agent and is currently in phase II clinical trials for chronic kidney disease and DKD.


Subject(s)
Renal Insufficiency, Chronic , Ureteral Obstruction , Rats , Humans , Animals , Soluble Guanylyl Cyclase/metabolism , Guanylate Cyclase/metabolism , Ureteral Obstruction/pathology , Kidney/metabolism , Disease Progression , Proteinuria/drug therapy , Fibrosis , Enalapril/therapeutic use , Nitric Oxide/metabolism , Cyclic GMP/metabolism
2.
Proc Natl Acad Sci U S A ; 116(20): 10156-10161, 2019 05 14.
Article in English | MEDLINE | ID: mdl-31028142

ABSTRACT

Transient receptor potential canonical type 6 (TRPC6) is a nonselective receptor-operated cation channel that regulates reactive fibrosis and growth signaling. Increased TRPC6 activity from enhanced gene expression or gain-of-function mutations contribute to cardiac and/or renal disease. Despite evidence supporting a pathophysiological role, no orally bioavailable selective TRPC6 inhibitor has yet been developed and tested in vivo in disease models. Here, we report an orally bioavailable TRPC6 antagonist (BI 749327; IC50 13 nM against mouse TRPC6, t1/2 8.5-13.5 hours) with 85- and 42-fold selectivity over the most closely related channels, TRPC3 and TRPC7. TRPC6 calcium conductance results in the stimulation of nuclear factor of activated T cells (NFAT) that triggers pathological cardiac and renal fibrosis and disease. BI 749327 suppresses NFAT activation in HEK293T cells expressing wild-type or gain-of-function TRPC6 mutants (P112Q, M132T, R175Q, R895C, and R895L) and blocks associated signaling and expression of prohypertrophic genes in isolated myocytes. In vivo, BI 749327 (30 mg/kg/day, yielding unbound trough plasma concentration ∼180 nM) improves left heart function, reduces volume/mass ratio, and blunts expression of profibrotic genes and interstitial fibrosis in mice subjected to sustained pressure overload. Additionally, BI 749327 dose dependently reduces renal fibrosis and associated gene expression in mice with unilateral ureteral obstruction. These results provide in vivo evidence of therapeutic efficacy for a selective pharmacological TRPC6 inhibitor with oral bioavailability and suitable pharmacokinetics to ameliorate cardiac and renal stress-induced disease with fibrosis.


Subject(s)
Cardiomegaly/drug therapy , Nephrosclerosis/drug therapy , TRPC6 Cation Channel/antagonists & inhibitors , Animals , Drug Evaluation, Preclinical , Fibrosis , HEK293 Cells , Heart/drug effects , Humans , Kidney/drug effects , Mice
3.
J Pharmacol Exp Ther ; 356(3): 712-9, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26729306

ABSTRACT

Therapies that restore renal cGMP levels are hypothesized to slow the progression of diabetic nephropathy. We investigated the effect of BI 703704, a soluble guanylate cyclase (sGC) activator, on disease progression in obese ZSF1 rats. BI 703704 was administered at doses of 0.3, 1, 3, and 10 mg/kg/d to male ZSF1 rats for 15 weeks, during which mean arterial pressure (MAP), heart rate (HR), and urinary protein excretion (UPE) were determined. Histologic assessment of glomerular and interstitial lesions was also performed. Renal cGMP levels were quantified as an indicator of target modulation. BI 703704 resulted in sGC activation, as evidenced by dose-dependent increases in renal cGMP levels. After 15 weeks of treatment, sGC activation resulted in dose-dependent decreases in UPE (from 463 ± 58 mg/d in vehicle controls to 328 ± 55, 348 ± 23, 283 ± 45, and 108 ± 23 mg/d in BI 703704-treated rats at 0.3, 1, 3, and 10 mg/kg, respectively). These effects were accompanied by a significant reduction in the incidence of glomerulosclerosis and interstitial lesions. Decreases in MAP and increases in HR were only observed at the high dose of BI 703704. These results are the first demonstration of renal protection with sGC activation in a nephropathy model induced by type 2 diabetes. Importantly, beneficial effects were observed at doses that did not significantly alter MAP and HR.


Subject(s)
Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/enzymology , Disease Progression , Enzyme Activators/pharmacology , Guanylate Cyclase/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/enzymology , Enalaprilat/chemistry , Enalaprilat/pharmacology , Enalaprilat/therapeutic use , Enzyme Activators/chemistry , Enzyme Activators/therapeutic use , Male , Rats , Rats, Zucker , Soluble Guanylyl Cyclase
4.
Drug Metab Dispos ; 42(10): 1751-60, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25035284

ABSTRACT

BIBX1382 was an epidermal growth factor receptor inhibitor under clinical investigation for treatment of cancer. This candidate possessed an attractive preclinical absorption, distribution, metabolism, and excretion profile, yet failed in clinical studies due in part to poor oral exposure, resulting from extensive metabolism by aldehyde oxidase (AO). In vitro metabolism studies were performed in liver cytosol and cryopreserved hepatocytes from multiple species. In addition, a pharmacokinetic study was performed in cynomolgus monkey for comparison with the reported human pharmacokinetics of BIBX1382. Estimated hepatic clearance of BIBX1382 in rhesus (42 ml/min per kg) and cynomolgus monkey (43 ml/min per kg) liver cytosol was comparable to human (≥93% of liver blood flow). Metabolite identification after incubation of BIBX1382 in liver cytosol fortified with the AO inhibitor raloxifene confirmed that AO is involved in the formation of the predominant metabolite (BIBU1476, M1) in cynomolgus monkey. After intravenous and oral administration of BIBX1382 to cynomolgus monkeys, high plasma clearance (118 ml/min per kg) and low oral exposure (C(max) = 12.7 nM and 6% oral bioavailability) was observed, with the exposure of M1 exceeding BIBX1382 after oral dosing. This pharmacokinetic profile compared favorably with the human clinical data of BIBX1382 (plasma clearance 25-55 ml/min per kg and 5% oral bioavailability). Thus, it appears that cynomolgus monkey represents a suitable surrogate for the observed human AO metabolism of BIBX1382. To circumvent clinical failures due to uncharacterized metabolism by AO, in vitro studies in the appropriate subcellular fraction, followed by pharmacokinetic and toxicokinetic studies in the appropriately characterized surrogate species should be conducted for substrates of AO.


Subject(s)
Aldehyde Oxidase/metabolism , ErbB Receptors/antagonists & inhibitors , Organic Chemicals/metabolism , Aldehyde Oxidase/antagonists & inhibitors , Animals , Biological Availability , Cytosol/metabolism , Dogs , Hepatocytes/metabolism , Humans , Liver/metabolism , Macaca fascicularis , Macaca mulatta , Organic Chemicals/blood , Raloxifene Hydrochloride/pharmacology , Rats
5.
Naunyn Schmiedebergs Arch Pharmacol ; 397(10): 8101-8116, 2024 10.
Article in English | MEDLINE | ID: mdl-38789635

ABSTRACT

This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 after oral single rising doses (SRDs) or multiple rising doses (MRDs) in healthy volunteers. In the SRD trial (NCT02694354; February 29, 2016), within each of the three dose groups (DGs), six subjects received BI 685509 (1.0, 2.5, or 5.0 mg) and two received placebo (N = 24). In the MRD trial (NCT03116906; April 17, 2017), within each of the five DGs, nine subjects received BI 685509 (uptitrated to 1 mg once daily [qd; DG1], 2.5 mg twice daily [DG2], 5.0 mg qd [DG3]; 3.0 mg three times daily [tid; DG4] or 4.0 mg tid [DG5]) and three received placebo, for 14-17 days (N = 60). In the SRD trial, 7/24 subjects (29.2%) had ≥ 1 adverse event (AE), most frequently orthostatic dysregulation (n = 4). In the MRD trial, 26/45 subjects (57.8%) receiving BI 685509 had ≥ 1 AE, most frequently orthostatic dysregulation and fatigue (each n = 12). Tolerance development led to a marked decrease in orthostatic dysregulation events (DG3). BI 685509 was rapidly absorbed after oral administration, and exposure increased in a dose-proportional manner after single doses. Multiple dosing resulted in near-dose-proportional increase in exposure and limited accumulation. BI 685509 pharmacokinetics appeared linear with time; steady state occurred 3-5 days after each multiple-dosing period. Increased plasma cyclic guanosine monophosphate and decreased blood pressure followed by a compensatory increase in heart rate indicated target engagement. BI 685509 was generally well tolerated; orthostatic dysregulation may be appropriately countered by careful uptitration.


Subject(s)
Healthy Volunteers , Humans , Male , Adult , Female , Double-Blind Method , Middle Aged , Young Adult , Dose-Response Relationship, Drug , Guanylyl Cyclase C Agonists/pharmacokinetics , Guanylyl Cyclase C Agonists/administration & dosage , Guanylyl Cyclase C Agonists/adverse effects , Guanylyl Cyclase C Agonists/pharmacology , Soluble Guanylyl Cyclase/metabolism , Administration, Oral , Blood Pressure/drug effects , Adolescent
6.
Hepatol Commun ; 7(11)2023 11 01.
Article in English | MEDLINE | ID: mdl-37889522

ABSTRACT

BACKGROUND: Portal hypertension is a severe complication of cirrhosis. This Phase Ib study (NCT03842761) assessed the safety, tolerability, and pharmacokinetics of soluble guanylyl cyclase activator BI 685509 in patients with mild or moderate hepatic impairment (Child-Pugh [CP] A or B cirrhosis) and healthy volunteers (HVs). METHODS: In this single-center, randomized, placebo-controlled study, patients received BI 685509 (maximum doses: 1, 2, or 3 mg, twice daily [BID]) or placebo for 28 days. HVs received one 0.5 mg dose of BI 685509 or placebo. RESULTS: In total, 64 participants (CP-A, n=24; CP-B, n=25; HVs, n=15) were included; most commonly with NAFLD (36.7%), alcohol-associated (30.6%), or chronic viral hepatitis-related cirrhosis (28.6%). In patients with CP-A cirrhosis, drug-related adverse events (AEs) occurred in 5.6% of BI 685509-treated patients and 16.7% of placebo recipients. In patients with CP-B cirrhosis, drug-related AEs occurred in 26.3% of BI 685509-treated patients only. No serious AEs occurred in patients with CP-A cirrhosis; in patients with CP-B cirrhosis, serious AEs (not drug-related) occurred in 10.5% of BI 685509-treated patients and 16.7% of patients receiving placebo. BI 685509 was rapidly absorbed; exposure increased with dosage and was similar between etiologies and between patients with CP-A cirrhosis and patients with CP-A cirrhosis but lower in HVs. The mean percentage portal-systemic shunt fraction was measured in patients with CP-A cirrhosis and decreased at the end of treatment in the 2 mg BID (-11.2 ± 11.9%) and 3 mg BID (-14.0 ± 8.4%) BI 685509 dose groups, but not in the placebo group (+1.0 ± 27.3%). CONCLUSION: BI 685509 was generally well tolerated, with 3 serious, not drug-related AEs reported in patients with CP-B cirrhosis. In patients with CP-A cirrhosis, portal-systemic shunt fraction in the exploratory efficacy analysis was reduced by 2 mg BID and 3 mg BID BI 685509.


Subject(s)
Liver Cirrhosis , Humans , Soluble Guanylyl Cyclase , Liver Cirrhosis/complications , Liver Cirrhosis/drug therapy
7.
Nature ; 440(7083): 505-7, 2006 Mar 23.
Article in English | MEDLINE | ID: mdl-16554813

ABSTRACT

An important and perhaps critical clue to the mechanism driving the explosion of massive stars as supernovae is provided by the accumulating evidence for asymmetry in the explosion. Indirect evidence comes from high pulsar velocities, associations of supernovae with long-soft gamma-ray bursts, and asymmetries in late-time emission-line profiles. Spectropolarimetry provides a direct probe of young supernova geometry, with higher polarization generally indicating a greater departure from spherical symmetry. Large polarizations have been measured for 'stripped-envelope' (that is, type Ic; ref. 7) supernovae, which confirms their non-spherical morphology; but the explosions of massive stars with intact hydrogen envelopes (type II-P supernovae) have shown only weak polarizations at the early times observed. Here we report multi-epoch spectropolarimetry of a classic type II-P supernova that reveals the abrupt appearance of significant polarization when the inner core is first exposed in the thinning ejecta (approximately 90 days after explosion). We infer a departure from spherical symmetry of at least 30 per cent for the inner ejecta. Combined with earlier results, this suggests that a strongly non-spherical explosion may be a generic feature of core-collapse supernovae of all types, where the asphericity in type II-P supernovae is cloaked at early times by the massive, opaque, hydrogen envelope.

8.
Appl Opt ; 47(31): G149-57, 2008 Nov 01.
Article in English | MEDLINE | ID: mdl-19122696

ABSTRACT

A comprehensive investigation of laser-induced breakdown spectroscopy (LIBS) at 1.500 microm of residues of six organic compounds (anthracene, caffeine, glucose, 1,3-dinitrobenzene, 2,4-dinitrophenol, and 2,4-dinitrotoluene) on aluminum substrates is presented and compared with LIBS at the Nd:YAG fundamental wavelength of 1.064 microm. The overall emission intensities were found to be smaller at 1.500 microm than at 1.064 microm, and the ratios of C(2) and CN molecular emissions to the H atomic emissions were observed to be less. Possible reasons for the observed differences in LIBS at 1.064 microm versus 1.500 microm are discussed.

9.
Spectrochim Acta A Mol Biomol Spectrosc ; 67(3-4): 1019-24, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17088097

ABSTRACT

Mid-infrared cavity ring-down spectroscopy (CRDS) has been employed in this study to examine the hydride stretching region of methyl azide and its pyrolysis product methyleneimine. The absorption spectrum of methyl azide over 2835-3085 cm(-1) was recorded, and the integrated absorption cross section was determined. The pyrolysis of methyl azide and subsequent production of methyleneimine was observed at various wavenumbers. Using IR CRDS, we were able to observe vibrational transitions of methyleneimine without interference from the methyl azide precursor. Our previous UV CRDS study showed that electronic transitions of methyleneimine overlapped with those of methyl azide. IR CRDS should thus be useful for the detection of polyatomic transient intermediates without interference from precursors.


Subject(s)
Azides/chemistry , Imines/chemistry , Incineration , Spectrophotometry, Infrared , Spectrophotometry, Ultraviolet , Imines/chemical synthesis
10.
Appl Spectrosc ; 59(8): 1068-74, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16105218

ABSTRACT

An improved method for qualitative and quantitative sampling of bacterial endospores using Fourier transform infrared (FT-IR) microscopy on gold-coated porous alumina membranes is presented. Bacillus subtilis endospores were filtered onto gold-coated alumina membranes serving as substrates. Studies in the mid-infrared (MIR) region revealed the characteristic bacterial absorption spectrum at low surface concentration, while scanning electron microscopy (SEM) images of the same samples provided precise calculation of the surface concentration of the bacterial endospores. Under the conditions of study, the average concentration of endospores was determined to be 1356 +/- 35 spores in a 100 x 100 mum(2) area, with a relative standard deviation of 0.0260. Examination of ten random spots on multiple substrates with FT-IR microscopy apertured to the same area gave an average relative standard deviation of 0.0482 in the signal strength of the amide A band at 3278 cm(-1). An extinction cross-section in reflection of sigma(ext) = (7.8 +/- 0.6) x 10(-9) cm(2)/endospore was calculated for the amide A band at the frequency of its peak absorbance, 3278 cm(-1). The absorption cross-section of the amide A band in reflection is estimated to be sigma(abs) approximately (2.10 +/- 0.12) x 10(-9) cm(2)/endospore.


Subject(s)
Aluminum Oxide/chemistry , Gold/chemistry , Micropore Filters , Spores, Bacterial/chemistry , Spores, Bacterial/isolation & purification , Bacillus subtilis/cytology , Bacillus subtilis/isolation & purification , Bacillus subtilis/ultrastructure , Filtration , Microscopy, Electron, Scanning , Porosity , Spectroscopy, Fourier Transform Infrared , Spores, Bacterial/ultrastructure
11.
Pediatr Dent ; 27(6): 505-12, 2005.
Article in English | MEDLINE | ID: mdl-16532893

ABSTRACT

PURPOSE: The purpose of this study was to investigate Chinese parents' beliefs and perspectives regarding extensive caries (EC), oral care habits, and dental treatment. An overview of qualitative research methods is provided. METHODS: In this qualitative study, 20 in-depth interviews were conducted with parents of children diagnosed with EC. Parents lived in a major metropolitan area, and many were newly immigrated. Parents who accepted or refused dental treatment for their children under general anesthesia or sedation were included. Transcribed interviews were analyzed using standard thematic analysis. RESULTS: Negative themes were: (1) fear of dental anesthesia and its adverse effects; (2) parents' own lack of dental education as children; (3) lack of social support in seeking dental treatment; (4) inadequate knowledge of oral hygiene; and (5) cultural beliefs that did not support the preservation of the primary dentition. Positive themes were: (1) trust in the providers and in Western medicine; and (2) satisfaction with outcomes of dental treatment. CONCLUSIONS: Several factors were found that could contribute to a higher rate of EC in this population. Providers can benefit from this study by anticipating what practices and attitudes are common in this community. Earlier intervention and delivery of culturally sensitive care can prevent or delay progression of this dental disease.


Subject(s)
Asian/psychology , Dental Care/psychology , Dental Caries/psychology , Health Knowledge, Attitudes, Practice , Parents/psychology , Child , Child, Preschool , China/ethnology , Culture , Dental Anxiety/psychology , Dental Care/statistics & numerical data , Female , Health Education, Dental , Humans , Interviews as Topic , Male , New York City , Oral Health , Oral Hygiene/psychology , Oral Hygiene/statistics & numerical data , Qualitative Research
12.
Clin Pharmacokinet ; 42(2): 193-204, 2003.
Article in English | MEDLINE | ID: mdl-12537517

ABSTRACT

OBJECTIVE: There are few analytical results that describe patient compliance with drug administration regimens. The purpose of this paper is to develop and assess stochastic approaches for mathematical modelling of patient compliance with administration regimens. METHODS: Two stochastic models based on Markov-dependent random variables and on the Ising model were assessed for their ability to describe the variable nature of drug compliance. RESULTS: Both models use only experimentally accessible data, and their predictions were tested against published clinical compliance data obtained from electronic monitoring devices. The models satisfactorily fitted administration interval distribution data from several patients treated with diltiazem, a calcium channel antagonist, or zidovudine, an antiretroviral agent. The Ising model provides additional analytical expressions for the distribution of success runs and 'drug holidays' in administration regimens. These distribution predictions were tested with success run data for diltiazem and drug holiday data for two nonsteroidal anti-inflammatory drugs, piroxicam and tenoxicam. CONCLUSIONS: Stochastic models can provide useful insights into drug compliance, and can be used to identify the administration patterns that are more likely to occur during drug self-administration in populations.


Subject(s)
Patient Compliance/statistics & numerical data , Algorithms , Humans , Markov Chains , Models, Statistical , Models, Theoretical , Reproducibility of Results , Stochastic Processes
13.
Can J Urol ; 6(3): 812-818, 1999 Jun.
Article in English | MEDLINE | ID: mdl-11178607

ABSTRACT

PURPOSE: To analyze the predictive value of early postnatal ultrasonography in congenital hydronephrosis. SUBJECTS AND METHODS: A retrospective study was conducted of 77 affected infants at our institution. All postnatal ultrasound studies were evaluated using 2 classification systems, the Anterior-Posterior Diameter (APD) system and the Society for Fetal Urology (SFU) system. Each study was compared to subsequent ultrasound examinations, renal scans, and to clinical outcome. RESULTS: There were 115 dilated renal units. Fifteen (13%) underwent intervention; all initially had high grade hydronephrosis on both classification systems. One hundred renal units (87%) were managed conservatively; 47 had low grade hydronephrosis and only 18 had high grade hydronephrosis on both systems. CONCLUSIONS: Using both the APD and the SFU classification systems together on the initial postnatal ultrasound is superior to using either method on its own, and the combined system enables us to predict the outcome of infants with congenital hydronephrosis.

14.
Clin Ther ; 33(7): 934-45, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21722960

ABSTRACT

BACKGROUND: Vitamin B12 (cobalamin) deficiency may be caused by inadequate dietary intake of B12 or by conditions that result in malabsorption of the vitamin. Crystalline vitamin B12, usually in the form of cyanocobalamin, is administered parenterally (ie, intramuscularly) or orally for treating deficiency states. Intramuscular administration is widely accepted as a treatment method. Oral B12 supplementation is also used, but it is considered to be less reliable. OBJECTIVE: This study was conducted to compare the pharmacokinetics and tolerability of 2 oral formulations of cyanocobalamin-a marketed cyanocobalamin tablet (immediate-release B12 5 mg) and cyanocobalamin formulated with a proprietary carrier, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC)-to establish the feasibility of using an absorption enhancer with B12 to improve uptake of the vitamin. This was the first clinical study conducted with the cyanocobalamin/SNAC coformulation. METHODS: An open-label, randomized, single-dose, parallel-group study was conducted in healthy male subjects. Subjects were randomly assigned to 1 of 4 treatment groups: Treatment A subjects (n = 4) received 2 tablets of 5-mg cyanocobalamin formulated with 100-mg SNAC as part of a dose range-finding arm included to determine a dose to provide a measurable concentration of vitamin B12 at all time points when tested with the available vitamin B12 assay; treatment B subjects (n = 6) received 1 tablet of 5-mg cyanocobalamin formulated with 100-mg SNAC; treatment C subjects (n = 6) received 1 commercially available 5-mg cyanocobalamin tablet; and treatment D subjects (n = 4) received commercially available 1-mg cyanocobalamin IV. Treatment A was completed 3 weeks before treatments B, C, and D were studied. Human serum B12 was analyzed by chemiluminescence assay method. Validation procedures established that samples could be diluted up to 100 times without any effects on accuracy and precision. The pharmacokinetic properties of vitamin B12 were characterized by noncompartmental analysis. Vitamin B12 absolute bioavailability estimates were calculated between the oral (A, B, and C) and IV (D) treatments using non-baseline-adjusted vitamin B12 concentrations as well as baseline-adjusted vitamin B12 concentrations, with or without body weight adjustments. Tolerability was evaluated through review or monitoring of medical history, physical examination findings, concomitant medications, vital signs, laboratory tests (hematology, serum chemistry, and urinalysis values), electrocardiography, adverse events, and serious adverse events. RESULTS: Twenty healthy male subjects, aged 20 to 45 years, participated in this study. Based on data from treatment A, a 5-mg cyanocobalamin dose was selected for use with treatments B and C. The oral cyanocobalamin formulation containing SNAC had greater mean absolute bioavailability than the commercial oral formulation (5.09% vs 2.16%, respectively), calculated on AUC(0-last) values uncorrected for baseline, weight, or body mass index. It also had a reduced T(max) compared with the commercial formulation (0.5 hours vs 6.83 hours, respectively). The K(e) was similar between treatments (0.028 1/h vs 0.025 1/h). Comparable results were achieved using corrected values. The cyanocobalamin/SNAC formulation was well tolerated, and there were no reported adverse events. CONCLUSIONS: An oral formulation of 5-mg cyanocobalamin containing 100-mg SNAC, an absorption enhancer, provided significantly improved bioavailability and a significant decrease in T(max) for B12 in a small study of normal healthy subjects compared with a commercially available 5-mg cyanocobalamin oral formulation. Both oral formulations and commercial 1-mg cyanocobalamin IV were well tolerated.


Subject(s)
Caprylates/chemistry , Drug Carriers/chemistry , Vitamin B 12/pharmacokinetics , Vitamin B Complex/pharmacokinetics , Administration, Oral , Adult , Area Under Curve , Biological Availability , Dose-Response Relationship, Drug , Feasibility Studies , Humans , Male , Middle Aged , Tablets , Time Factors , Vitamin B 12/administration & dosage , Vitamin B 12/adverse effects , Vitamin B Complex/administration & dosage , Vitamin B Complex/adverse effects , Young Adult
15.
J Med Chem ; 54(16): 5868-77, 2011 Aug 25.
Article in English | MEDLINE | ID: mdl-21744827

ABSTRACT

By use of parallel chemistry coupled with physicochemical property design, a series of selective κ opioid antagonists have been discovered. The parallel chemistry strategy utilized key monomer building blocks to rapidly expand the desired SAR space. The potency and selectivity of the in vitro κ antagonism were confirmed in the tail-flick analgesia model. This model was used to build an exposure-response relationship between the κ K(i) and the free brain drug levels. This strategy identified 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242, which entered phase 1 clinical testing and has demonstrated target engagement in healthy volunteers.


Subject(s)
Biphenyl Compounds/pharmacology , Drug Design , Drug Discovery , Narcotic Antagonists/pharmacology , Receptors, Opioid, kappa/antagonists & inhibitors , Sulfonamides/pharmacology , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , Analgesics/chemistry , Analgesics/pharmacokinetics , Analgesics/pharmacology , Animals , Area Under Curve , Biphenyl Compounds/chemistry , Biphenyl Compounds/pharmacokinetics , Brain/metabolism , Disease Models, Animal , Dogs , Haplorhini , Humans , Metabolic Clearance Rate , Mice , Microsomes, Liver/metabolism , Models, Chemical , Molecular Structure , Morphine/pharmacology , Narcotic Antagonists/chemistry , Narcotic Antagonists/pharmacokinetics , Pain/metabolism , Pain/prevention & control , Rats , Rats, Sprague-Dawley , Receptors, Opioid, kappa/agonists , Receptors, Opioid, kappa/metabolism , Receptors, Opioid, mu/agonists , Structure-Activity Relationship , Sulfonamides/chemistry , Sulfonamides/pharmacokinetics
16.
J Med Chem ; 54(21): 7602-20, 2011 Nov 10.
Article in English | MEDLINE | ID: mdl-21928839

ABSTRACT

The discovery of two histamine H(3) antagonist clinical candidates is disclosed. The pathway to identification of the two clinical candidates, 6 (PF-03654746) and 7 (PF-03654764) required five hypothesis driven design cycles. The key to success in identifying these clinical candidates was the development of a compound design strategy that leveraged medicinal chemistry knowledge and traditional assays in conjunction with computational and in vitro safety tools. Overall, clinical compounds 6 and 7 exceeded conservative safety margins and possessed optimal pharmacological and pharmacokinetic profiles, thus achieving our initial goal of identifying compounds with fully aligned oral drug attributes, "best-in-class" molecules.


Subject(s)
Cyclobutanes/chemical synthesis , Drug Design , Histamine Antagonists/chemical synthesis , Pyrrolidines/chemical synthesis , Receptors, Histamine H3/metabolism , Animals , Blood Proteins/metabolism , Blood-Brain Barrier/metabolism , Cell Line , Cyclobutanes/pharmacology , Cyclobutanes/toxicity , Dogs , Drinking Behavior/drug effects , High-Throughput Screening Assays , Histamine Antagonists/pharmacology , Histamine Antagonists/toxicity , Humans , In Vitro Techniques , Kidney/metabolism , Lipidoses/chemically induced , Lipidoses/metabolism , Lung/metabolism , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Models, Molecular , Molecular Structure , Phospholipids/metabolism , Protein Binding , Pyrrolidines/pharmacology , Pyrrolidines/toxicity , Rats , Rats, Sprague-Dawley , Stereoisomerism , Structure-Activity Relationship
17.
J Med Chem ; 53(3): 1222-37, 2010 Feb 11.
Article in English | MEDLINE | ID: mdl-20043678

ABSTRACT

A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.


Subject(s)
Azabicyclo Compounds/chemical synthesis , Azabicyclo Compounds/pharmacology , Cognition Disorders/drug therapy , Nicotinic Agonists/chemical synthesis , Nicotinic Agonists/pharmacology , Nootropic Agents/chemical synthesis , Nootropic Agents/pharmacology , Oxazoles/chemical synthesis , Oxazoles/pharmacology , Receptors, Nicotinic/chemistry , Schizophrenia/drug therapy , Animals , Azabicyclo Compounds/chemistry , Biological Availability , Cells, Cultured , Epithelial Cells/drug effects , Female , Hippocampus/drug effects , Humans , Kidney/cytology , Kidney/drug effects , Microsomes, Liver/drug effects , Nicotinic Agonists/chemistry , Nootropic Agents/chemistry , Oocytes/drug effects , Oxazoles/chemistry , Rats , Skin/cytology , Skin/drug effects , Structure-Activity Relationship , Xenopus laevis/growth & development , alpha7 Nicotinic Acetylcholine Receptor
18.
Drug Metab Dispos ; 33(1): 165-74, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15502009

ABSTRACT

Thirty-two structurally diverse drugs used for the treatment of various conditions of the central nervous system (CNS), along with two active metabolites, and eight non-CNS drugs were measured in brain, plasma, and cerebrospinal fluid in the P-glycoprotein (P-gp) knockout mouse model after subcutaneous administration, and the data were compared with corresponding data obtained in wild-type mice. Total brain-to-plasma (B/P) ratios for the CNS agents ranged from 0.060 to 24. Of the 34 CNS-active agents, only 7 demonstrated B/P area under the plasma concentration curve ratios between P-gp knockout and wild-type mice that did not differ significantly from unity. Most of the remaining drugs demonstrated 1.1- to 2.6-fold greater B/P ratios in P-gp knockout mice versus wild-type mice. Three, risperidone, its active metabolite 9-hydroxyrisperidone, and metoclopramide, showed marked differences in B/P ratios between knockout and wild-type mice (6.6- to 17-fold). Differences in B/P ratios and cerebrospinal fluid/plasma ratios between wild-type and knockout animals were correlated. Through the use of this model, it appears that most CNS-active agents demonstrate at least some P-gp-mediated transport that can affect brain concentrations. However, the impact for the majority of agents is probably minor. The example of risperidone illustrates that even good P-gp substrates can still be clinically useful CNS-active agents. However, for such agents, unbound plasma concentrations may need to be greater than values projected using receptor affinity data to achieve adequate receptor occupancy for effect.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B/deficiency , Central Nervous System Agents/metabolism , Central Nervous System/metabolism , Drug Delivery Systems/methods , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/deficiency , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP-Binding Cassette Transporters/genetics , Animals , Central Nervous System/drug effects , Central Nervous System Agents/administration & dosage , Female , Mice , Mice, Knockout , ATP-Binding Cassette Sub-Family B Member 4
SELECTION OF CITATIONS
SEARCH DETAIL